deaths from tirzepatide GROUNDBREAKING UPDATE! FDA has approved TIRZEPATIDE, a pioneering obesity treatment activating GIP & GLP-1 receptors, for weight loss! Previously, has been FDA approved for type 2 diabetes as Mounjaro, and although Mounjaro, Zepbound Lowers Risk of

The elevated calcium levels enhance insulin release through the Gq/phospholipase C pathway, where inositol trisphosphate (IP3) and diacylglycerol activate their respective receptors, the IP3 receptor (IP3R) and the ryanodine receptor, triggering calcium release ( Figure 1 ) [11]

It is just not what it is being marketed as

One commenter suggested that Safety of Care measures may not sufficiently account for clinical complexity, particularly for large tertiary hospitals and those performing high volumes of complex cases, which could obscure meaningful quality differences and discourage hospitals from treating high-risk patients

Tak YJ, Lee SY